Navigation Links
Ad hoc: Interim report about clinical trial of BF-200 ALA in,actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announced that an interim report regarding the clinical study of BF-200 ALA in actinic keratosis was received today from an independent review committee. The objectives of the study are to investigate the efficacy and safety of several doses of BF-200 ALA in photodynamic therapy. The comments received today refer to the clinical results eight weeks after treatment. An additional report about the results after twelve weeks will follow.

The interim committee reported that no side effect justifying concerns about the safety of this dose were observed in any dose group. On the basis of the available data, the therapy was found to be safe for all doses tested.

In spite of the limited patient number, different doses gave rise to clear differences in efficacy. However, the results of the different doses were not yet disclosed. The committee announced this disclosure once it has received and analyzed the clinical results 12 weeks after treatment. Biofrontera expects this second report within few weeks.

To optimize the statistical study design, the committee has proposed to continue the phase III part of the study separately. This will enable the complete analysis of the 12-week data. On this basis, Biofrontera intends to continue the further development of the 10 % dose, provided this dose selection is supported by the 12-week data.

Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Germany ISIN: DE0006046113 WKN: 604611

Contact: Anke zur Mühlen Biofrontera AG Tel.: +49 (0214) 87 63 222 Fax.: +49 (0214) 87 63 290 e-mail: a.zurmuehlen@biofrontera.com


'"/>




Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: hoc Interim report about clinical trial ALA actinic keratosis
(Date:7/29/2014)... 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... two healthcare conferences during the third quarter, the 2014 ... Global Healthcare 2014 Conference.  Alexza,s corporate presentation will be ... on each event are below: , 2014 ... in Boston , MA.  The format ...
(Date:7/29/2014)... -- Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today reported net income for the quarter ended June ... and non-GAAP net income of $94.0 million, or $0.88 per ... earlier was $93.3 million, or $0.81 per diluted share, and ... share.  Net sales for the quarter ended ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... GTHR.PK), announces it will soon begin offering its Real Time,PCR ... , GeneThera is set ... January of 2009. According to GeneThera Chairman, Dr. Tony ... PCR test for Johne,s disease,called HerdGuard(TM) by the first of ...
... A new cancer treatment is,realizing outstanding results against ... large, stage 4 tumor was reduced in size ... no longer could be definitely,identified on scans. Pancreatic ... diagnosis. NeoPlas Innovation,s combination of FDA-approved drugs,appears to ...
Cached Medicine Technology:GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4New Cancer Treatment Shrinks Pancreatic Tumor 2
(Date:7/29/2014)... LEBANON, NH (July 29, 2014) Using quality improvement ... Northern New England Cardiovascular Disease Study Group, researchers have ... undergoing a procedure with contrast dye. , Currently, 7-15 ... procedure with contrast-dye end up with kidney injury, which ... function leading to temporary or permanent dialysis, says a ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a ... celebrated throughout that time by picnics, barbecues and beach ... mark the start of a period that will witness ... In 2012 nearly 1.000 people were killed in crashes ... to Labor Day. , The summer's warmer weather, longer ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 During his 37 ... Bruce, DMD & Associates, has had a steady stream of ... dentistry. These students have now gone on to dental school ... proving that the shadowing program helps college students find success. ... Bruce has given them the chance to see a realistic ...
(Date:7/29/2014)... A team of scientists, led by ... has developed a blood test for Alzheimer’s disease risk ... of Alzheimer’s disease interventions, according to an article published ... and this study represents one of several pieces that ... couple of years,” Ethell said. , The study, “Women ...
(Date:7/29/2014)... July 29, 2014 Just months after ... to 4 new states, the exciting FX family does ... and one time farmboy from Arkansas, is shocking the ... innovative event technologies to the masses. This time ... packed island of Jamaica. This new office is ...
Breaking Medicine News(10 mins):Health News:Reducing kidney injury using a quality improvement method 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Arthur Bruce Dental Helps College Students 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Atlanta Special FX Rapidly Expanding Just Opens First International Corporate Office in Jamaica 2
... to Ensure Equitable Protections,for All Americans and Their ... America,s,Health (TFAH) issued the following statement on the ... Services(HHS) Draft Guidances to Assist in,Preparation for an ... government must do all it can to ensure ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... Schroeder will present the corporate overview on,Wednesday, June ... pm Pacific Time),during the Seventh Annual Needham & ...
... DALLAS, June 4 The echocardiography lab ... by the,Inter-societal Commission for the Accreditation of ... two hospitals in the region,accredited by the ... is paramount," said Dr.,Jorge Cheirif, Presbyterian,s chief ...
... abuse after college as well as face ... College students with a "dense" family history of alcoholism ... study says. , While most university students tend to ... young adults, some develop alcohol-use disorders, or AUDs. Most ...
... participants saw urine protein levels lowered significantly , , WEDNESDAY, June ... to combat some of the damaging effects of type 2 ... a new Danish study has found. , But ... and aliskiren (Tekturna) to block the activity of a molecule ...
... progress among Hispanic children , , WEDNESDAY, June 4 (HealthDay ... to engage in risky health behaviors, including sexual intercourse, ... U.S. health officials said Wednesday. , While there have ... students, Hispanic students remain at higher risk for some ...
Cached Medicine News:Health News:Trust for America's Health on New HHS Influenza Pandemic Draft Guidance 2Health News:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York 2Health News:Echocardiography Lab at Presbyterian Hospital of Dallas Achieves Prestigious Reaccreditation 2Health News:Family History of Alcoholism Puts Student Drinkers at Risk 2Health News:Two-Drug Combo Reduces Diabetic Kidney Damage 2Health News:Two-Drug Combo Reduces Diabetic Kidney Damage 3Health News:Fewer U.S. High School Students Engage in Risky Behaviors 2Health News:Fewer U.S. High School Students Engage in Risky Behaviors 3
... Spatula Tips That Mimic Corneal Curvature. Designed To ... Created With The IntraLase TMFS Laser System., ... Of The Forceps Are Designed To Facilitate Access ... Achieved, The Cross-Action Forceps Design Allows The Surgeon ...
... Allowing The Exact,Outer Diameter Measurement Of A ... ,Increments.,Easy And Quick To Use, With One-HandedOperation. ... Over A Cornea For Confirmation Of Exact ... ,Guaranteed For ...
... Safely And Easily Cut Foldable Lenses Through ... The Incision., ,Specially Designed To Cut And ... Lenses With Ease With One Instrument., ,Ideal ... Lenses Which Are Damaged, The Wrong Diopter ...
... Gauge Measures 360 Degrees & Can Be ... A Cornea. 7mm Inner Diameter & 14mm Outer ... Only Astigmatism Gauge That Can Be Set For ... Degree Around The Globe., ,Marks Single Or Paired ...
Medicine Products: